ClinicalTrials.gg
RecruitingNCT07227961Updated Nov 2, 2026

Activation Sarcoma: PROMIS and Mobility Evaluation in Sarcoma Patients

An observational study in Sarcoma and Giant Cell Tumor of Bone, sponsored by University of Calgary. Recruiting at 4 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-02.

Sponsored by University of Calgary · Observational

How we know

From the registry’s dates

  • Started Jul 2025; still recruiting 1 year 4 months later.
Updated Nov 2, 2026Study documents postedSite recruiting status changed+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
800
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 958 studies in Sarcoma with a site in United States — 153 open to participants now, 242 under way, 4 of them phase 3. Sarcoma · United States.

Planned enrollment
25th of 100
800 · median 101
Started
2025
with 43 others
Observational
100 of 958
30 open now
Primary completion
2030-06
later than 208 of 240 live
Registered
928th of 958
by date

Among the 958 studies in Sarcoma with a site in United States, this one is the 25th largest by planned enrollment of the 100 observational ones that give a count, is one of 44 that started in 2025, is one of 100 observational ones, reaches primary completion later than 208 of the 240 other live ones, and was the 928th registered.

Sarcoma

1,610 studies on the registry are indexed under Sarcoma; 367 are open to participants now.

Browse Sarcoma studies →

Open to participants now

153 of the 958 studies in Sarcoma with a site in United States are open now. Recruiting first, the newest first:

148 more — sign in →

All 153 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 302 Sarcoma studies recruiting now, 192 (64%) set no upper age limit and 83 (27%) stop at 75 or younger; 94 take children under 18; 12 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 958 studies in Sarcoma with a site in United States, or all of them as a file.
02

Study summary

Sarcoma is a rare form of bone and soft tissue cancer, making up about 1% of all adult cancers. Management typically involves radiation therapy, chemotherapy, and surgical resection. Surgery is central to the treatment of bone and soft tissue sarcoma, yet post-surgical recovery is difficult to measure because of disease rarity, multiple different tumor types, and treatment variation. Therefore, the overall goal of the study is to use patient reported outcome measures and mobility data to define recovery trajectories in sarcoma patients undergoing surgery, and to evaluate a novel smartphone application (app) entailed Activation Health for collecting these data.

Participants will download the Activation Health app on their smartphone. A demographics survey and multiple patient reported outcome measures will be administered remotely through the Activation Health app. Surveys will be completed preoperatively and at 6 weeks, 12 weeks, 6 months 12 months, 16 months, 20 months, and 24 months postoperatively. Additionally, the app will passively track mobility metrics such as daily step count, stairs climbed, and gait parameters throughout the study period. At the end of study participation, an additional surveys will be administered assess participant phone use habits and app function.

Read the detailed description

Background \& Rationale:

Sarcoma is a rare form of bone and soft tissue cancer, making up about 1% of all adult cancers. Management typically involves radiation therapy, chemotherapy, and surgical resection, with or without limb reconstruction. The diagnosis, intensive treatment regimen, and surgery-induced deficits significantly impact patient quality of life and function.

Surgery is central to the treatment of bone and soft tissue sarcoma, yet postoperative recovery is difficult to measure because of disease rarity, heterogeneity, and treatment variation. Legacy instruments such as the Toronto Extremity Salvage Score (TESS) have ceiling effects, limited health-domain coverage, and response burden. The Patient-Reported Outcomes Measurement Information System (PROMIS) uses short surveys across multiple health domains that may better capture recovery. PROMIS was developed with oncology research considerations and has been validated in both orthopaedic and oncology populations. However, the significance of PROMIS in orthopaedic oncology is not well understood.

Assessing patient reported outcomes is limited by survey completion rates, particularly in the oncology patients who have multiple medical appointments and care teams. To address these challenges, our team has developed Activation Health, a smartphone application (app) tailored to musculoskeletal oncology. Unlike general fitness or commercial health applications, Activation Health remotely administers patient reported outcome measures (PROMs) and passively captures mobility metrics. The continuous data collection aligns real-world mobility with clinical recovery timelines, offering a more precise view of patient outcomes.

The overall aim of the study is to validate the PROMIS as an outcome measure in the sarcoma population, and to evaluate the Activation Health app for remote PROM administration and mobility data collection.

Hypothesis:

PROMIS and mobility metrics will provide a holistic and granular view of recovery trajectories, and the use of a novel smartphone application will improve patient engagement and data collection.

Specific Aims:

  1. Compare the responsiveness of five PROMIS short forms to the TESS for assessing recovery after sarcoma surgery
  2. Determine the minimal clinically important differences (MCID) for five PROMIS short forms in the sarcoma population
  3. Assess the feasibility and usability of Activation Health for remote PROM survey administration and mobility data collection in the sarcoma population
  4. Correlate PROM scores with mobility metrics to define recovery trajectories after sarcoma surgery
  5. Identify demographic and socioeconomic factors that influence survey responses and engagement with the Activation Health app in the sarcoma population

Methods:

Recruitment and Sample Size:

This is a prospective, multicentre longitudinal cohort study involving the University of Calgary, University of Toronto, Mayo Clinic Rochester and Mayo Clinic Arizona. All eligible patients will be seen by a musculoskeletal oncology surgeons at one of the participating sites. Adult patients (≥18 years) diagnosed with an operative bone or soft tissue sarcoma are eligible for inclusion. Tumors can be primary or recurrent, and can be located in the upper extremities, pelvis, or lower extremities. Participants must speak English to be included in the study. The investigators anticipate enrolling approximately 800 sarcoma patients based on current surgical volumes and patient capture rates for collecting quality of life and functional data.

Data Collection:

Clinical data will be collected by an approved member of the research team using the local electronic medical record and a standardized case repot form. Participants will download the Activation Health app on their smartphone. A demographics survey, TESS, and PROMIS physical function, upper extremity, pain interference, global health, and self efficacy surveys will be administered remotely through the Activation Health app and Qualtrics. Completion of these surveys will be prompted via push notifications preoperative and at 6 weeks, 12 weeks, 6 months 12 months, 16 months, 20 months, and 24 months postoperative. Mobility metrics will be passively collected by the app throughout study involvement. The mobility metrics of interest include but are not limited to step count, distance travelled, move time, flights of stairs climbed, walking steadiness, walking asymmetry, double support time, walking speed, and step length. Additionally, physiological parameters such as maximum oxygen consumption (VO2 max) will be collected from participants with a compatible smartwatch. At the end of study participation, an additional surveys will be administered assess participant phone use habits and app function.

To improve study accessibility, participants without a compatible smartphone or unwilling to use the Activation Health app can contribute survey data using Qualtrics. The secure Qualtrics survey links will be distributed via email or text message (patient preference) by an approved member of the study team at pre-specified data collection timepoints. In addition, participants may contribute their mobility data at the end of study involvement during an in-person visit. For apple device users, secure data transfer can be facilitated via the AirDrop feature and for Android users via Google Takeout.

Statistical Analysis:

Summary statistics will describe population demographic and clinical characteristics. Continuous data will be represented as means with standard deviation or medians with interquartile range, and categorical data as proportions. Individual-level socioeconomic status will be calculated using household income, education level, and occupation.

The sensitivity of the PROMIS physical function and upper extremity function domains will be independently compared to the TESS using effect size and standardized response means. These measures will allow for comparison of whether the T-scores scores changed by a small or large amount over time. Additionally, the aggregate score of all the PROMIS domains will be compared to TESS. Aggregate scores will be calculated by averaging the five domain-specific T-scores. MCIDs for PROMIS domains will be calculated using an anchor-based method with the Global Rating of Change. The sensitivity of PROMIS will be compared to TESS using correlation coefficients, Bland-Altman plots, and linear regression models.

Mobility data will undergo principal component analysis to derive a composite index capturing the key features of interest. Ordinal logistic regression will be used to determine if mobility metrics collected form a smartphone are associated with patient-reported activity level, as assessed by a seven-point PGIC anchor question. Linear mixed-effects regression models will assess whether mobility changes are associated with changes in PROMIS and TESS scores.

The proportion of PROMIS and TESS questionnaires that are completed will be calculated. Logistic regression will be used to identify demographic factors that predict survey completion, with survey completion represented as a binary variable (yes or no).

03

Conditions studied

  • Sarcoma
  • Giant Cell Tumor of Bone

Keywords

  • Patient reported outcomes
  • PROMIS
  • TESS
  • Mobility
  • Recovery
  • Surgery
  • App
  • Digital health
  • Sarcoma
04

Who can participate

The criteria were revised on the registry on Nov 2, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The investigators will enrol patients under the care of a musculoskeletal oncology surgeon at Foothills Medical Centre (Calgary, AB, Canada), Mount Sinai Hospital (Toronto, ON, Canada), Mayo Clinic Arizona (Phoenix, AZ, United States), and Mayo Clinic Minnesota (Rochester, MN, United States).

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 years
  • Diagnosis of bone sarcoma, soft tissue sarcoma, or giant cell tumor of bone
  • Tumors located in the pelvis, lower extremities, or upper extremities
  • Primary or recurrent disease
  • Undergoing operative tumor resection, including limb salvage surgery and amputation
  • Has an iPhone or Android smartphone
  • Speaks English

Exclusion criteria

Exclusion Criteria:

  • bone tumor
  • Diagnosis of atypical lipomatous tumor
  • Diagnosis of dermatofibrosarcoma protuberans
  • Currently pregnant or planning pregnancy within 6 months
  • Unwilling or unable to attend follow-up evaluations
  • Cognitive or communication barriers that impede completion of questionnaires
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
800 participants (estimated)
Patient registry
No

Groups and cohorts

  • Sarcoma

    Adult patients treated with surgery for bone and soft tissue sarcoma, and giant cell tumor of bone

    Procedure: Surgery

Interventions

  • ProcedureSurgery

    Any type of surgery performed to remove the primary tumor including resection, amputation, and bone stabilization.

    Also known as: Operation, Procedure, Tumor resection, Amputation, Bone stabilization

06

What researchers measure

Primary outcomes

  1. Step count

    Number of steps

    Time frame: From enrolment to two years postoperative

  2. Distance travelled

    Kilometers

    Time frame: From enrolment two years postoperative

  3. Move time

    Minutes

    Time frame: From enrolment two years postoperative

  4. Flights of stairs climbed

    Number of flights climbed

    Time frame: From enrolment to two years postoperative

  5. Walking Steadiness

    Percentage

    Time frame: From enrolment two years postoperative

  6. Walking asymmetry

    Percentage

    Time frame: From enrolment two years postoperative

  7. Double Support Time

    Percentage

    Time frame: From enrolment two years postoperative

  8. Walking Speed

    Kilometers/hour

    Time frame: From enrolment two years postoperative

  9. Step Length

    Centimeters

    Time frame: From enrolment two years postoperative

  10. Heart rate variability

    Milliseconds. Measures the variation in time between each beat of your heart, with a higher score generally indicating better physical fitness.

    Time frame: From enrolment to two years postoperative

  11. PROMIS Physical Function

    Scored using standardized T-scores with a mean of 50 and a standard deviation of 10. Scores above 50 indicate more of the measured trait, while scores below 50 indicate less.

    Time frame: From enrolment to two years postoperative

  12. PROMIS Upper Extremity Function

    Scored using standardized T-scores with a mean of 50 and a standard deviation of 10. Scores above 50 indicate more of the measured trait, while scores below 50 indicate less.

    Time frame: From enrolment to two years postoperative

  13. PROMIS Pain Interference

    Scored using standardized T-scores with a mean of 50 and a standard deviation of 10. Scores above 50 indicate more of the measured trait, while scores below 50 indicate less.

    Time frame: From enrolment to two years postoperative

  14. PROMIS Global Health

    Scored using standardized T-scores with a mean of 50 and a standard deviation of 10. Scores above 50 indicate more of the measured trait, while scores below 50 indicate less.

    Time frame: From enrolment to two years postoperative

  15. PROMIS Self Efficacy

    Scored using standardized T-scores with a mean of 50 and a standard deviation of 10. Scores above 50 indicate more of the measured trait, while scores below 50 indicate less.

    Time frame: From enrolment to two years postoperative

  16. Toronto Extremity Salvage Score Lower Extremity

    Sum of patient responses for each question on a 5-point Likert scale, excluding "not applicable" items. The sum is then divided by the maximum possible score and multiplyed by 100 to yield a final score between 0 and 100. A score of 100 indicates no functional disability and 0 indicates the worst functional disability.

    Time frame: From enrolment to two years postoperative

  17. Toronto Extremity Salvage Score Upper Extremity

    Sum of patient responses for each question on a 5-point Likert scale, excluding "not applicable" items. The sum is then divided by the maximum possible score and multiplyed by 100 to yield a final score between 0 and 100. A score of 100 indicates no functional disability and 0 indicates the worst functional disability.

    Time frame: From enrolment to two years postoperative

  18. Demographic Survey

    Time frame: Enrolment

Secondary outcomes

  1. App Survey

    Survey administered at the end of study participation to assess satisfaction and user-friendliness of the ACTIVATION app using Liekert scales. Survey also contains three short answer responses collecting feedback about the app and gathering data on technical difficulties. Last section of the survey contains questions about phone use habits using multiple choice questions..

    Time frame: Single collection time point at 1 year post-operative.

07

Study locations

2 of 4 sites recruiting
  • Mayo Clinic
    Phoenix, Arizona 85054, United States
    Not yet recruiting
  • Mayo Clinic
    Rochester, Minnesota 55905, United States
    Not yet recruiting
    • Matthew T Houdek, MD · Contacthoudek.matthew@mayo.edu · 507-284-2995
    • Matthew T Houdek, MD · Principal investigator
  • Foothills Medical Centre, Arthur J Child Comprehensive Cancer Centre, University of Calgary
    Calgary, Alberta T2N 2T9, Canada
    Recruiting
    • Joseph K Kendal, MD MSc FRCSC · Contactjkkendal@ucalgary.ca · 403-944-4793
    • Alyssa A Federico, MD · Contactalyssa.federico@ucalgary.ca · 403-650-5071
    • Joseph K Kendal, MD MSc FRCSC · Principal investigator
    • Michael J Monument, MD MSc FRCSC · Sub investigator
    • Shannon Puloski, MD FRCSC · Sub investigator
  • Mount Sinai Hospital, University of Toronto
    Toronto, Ontario M5G 1X5, Canada
    Recruiting
    • Jay S Wunder, MD MSc FRCSC · Contactjay.wunder@sinaihealth.ca · 416-586-4800
    • Anthony Griffin, MSc · Contactanthony.griffin@sinaihealth.ca · 416-586-4800
    • Jay S Wunder, MD MSc FRCSC · Principal investigator
    • Peter C Ferguson, MD MSc FRCSC FAOA · Sub investigator
    • Aaron M Gazendam, MD MSc FRCSC · Sub investigator
    • Kim Tsoi, MD PhD FRCSC · Sub investigator
08

References and documents

Publications

  • Tyser AR, Beckmann J, Franklin JD, Cheng C, Hon SD, Wang A, Hung M. Evaluation of the PROMIS physical function computer adaptive test in the upper extremity. J Hand Surg Am. 2014 Oct;39(10):2047-2051.e4. doi: 10.1016/j.jhsa.2014.06.130. Epub 2014 Aug 16. PubMed 25135249 ↗
  • Hung M, Stuart AR, Higgins TF, Saltzman CL, Kubiak EN. Computerized Adaptive Testing Using the PROMIS Physical Function Item Bank Reduces Test Burden With Less Ceiling Effects Compared With the Short Musculoskeletal Function Assessment in Orthopaedic Trauma Patients. J Orthop Trauma. 2014 Aug;28(8):439-43. doi: 10.1097/BOT.0000000000000059. PubMed 24378399 ↗
  • Jensen RE, Potosky AL, Reeve BB, Hahn E, Cella D, Fries J, Smith AW, Keegan TH, Wu XC, Paddock L, Moinpour CM. Validation of the PROMIS physical function measures in a diverse US population-based cohort of cancer patients. Qual Life Res. 2015 Oct;24(10):2333-44. doi: 10.1007/s11136-015-0992-9. Epub 2015 May 3. PubMed 25935353 ↗
  • Blank AT, Lerman DM, Shaw S, Dadrass F, Zhang Y, Liu W, Hung M, Jones KB, Randall RL. PROMIS(R) scores in operative metastatic bone disease patients: A multicenter, prospective study. J Surg Oncol. 2018 Sep;118(3):532-535. doi: 10.1002/jso.25159. Epub 2018 Aug 16. PubMed 30114336 ↗
  • Garcia SF, Cella D, Clauser SB, Flynn KE, Lad T, Lai JS, Reeve BB, Smith AW, Stone AA, Weinfurt K. Standardizing patient-reported outcomes assessment in cancer clinical trials: a patient-reported outcomes measurement information system initiative. J Clin Oncol. 2007 Nov 10;25(32):5106-12. doi: 10.1200/JCO.2007.12.2341. PubMed 17991929 ↗
  • Ploetze KL, Dalton JF, Calfee RP, McDonald DJ, O'Keefe RJ, Cipriano CA. Patient-Reported Outcomes Measurement Information System physical function correlates with Toronto Extremity Salvage Score in an orthopaedic oncology population. J Orthop Translat. 2019 Mar 8;19:143-150. doi: 10.1016/j.jot.2019.02.004. eCollection 2019 Oct. PubMed 31844622 ↗
  • Ogura K, Uehara K, Akiyama T, Shinoda Y, Iwata S, Tsukushi S, Kobayashi E, Hirose T, Yonemoto T, Endo M, Tanzawa Y, Nakatani F, Kawano H, Tanaka S, Kawai A. Minimal clinically important differences in Toronto Extremity Salvage Score for patients with lower extremity sarcoma. J Orthop Sci. 2020 Mar;25(2):315-318. doi: 10.1016/j.jos.2019.03.022. Epub 2019 Apr 16. PubMed 31000377 ↗
  • Hassani M, Mate KKV, Turcotte R, Denis-Larocque G, Ghodsi E, Tsimicalis A, Goulding K. Uncovering the gaps: A systematic mixed studies review of quality of life measures in extremity soft tissue sarcoma. J Surg Oncol. 2023 Sep;128(3):430-437. doi: 10.1002/jso.27390. PubMed 37537979 ↗
  • Vijayakumar G, Blank AT. Patient-reported outcome tools in musculoskeletal oncology. J Surg Oncol. 2023 Sep;128(3):418-424. doi: 10.1002/jso.27386. PubMed 37537983 ↗
  • Goulding KA, Wilke BK, Kiernan HC, Houdek MT, Sherman CE. Skeletal Sarcomas: Diagnosis, Treatment, and Follow-up from the Orthopedic Oncologist Perspective. Radiol Clin North Am. 2022 Mar;60(2):193-203. doi: 10.1016/j.rcl.2021.11.001. PubMed 35236588 ↗
  • Gutowski CJ, Basu-Mallick A, Abraham JA. Management of Bone Sarcoma. Surg Clin North Am. 2016 Oct;96(5):1077-106. doi: 10.1016/j.suc.2016.06.002. PubMed 27542644 ↗
  • Walczak BE, Irwin RB. Sarcoma chemotherapy. J Am Acad Orthop Surg. 2013 Aug;21(8):480-91. doi: 10.5435/JAAOS-21-08-480. PubMed 23908254 ↗
  • Burningham Z, Hashibe M, Spector L, Schiffman JD. The epidemiology of sarcoma. Clin Sarcoma Res. 2012 Oct 4;2(1):14. doi: 10.1186/2045-3329-2-14. PubMed 23036164 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — To protect participant privacy and confidentiality, the investigators will not share IPD with other researchers. The study involves sensitive or identifiable health information and the consent obtained from participants does not include permission to share their individual-level data publicly or with third parties.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2025 (actual). Primary completion is estimated for Jun 2030, 59 months after the start.

Of 88 non-industry observational studies under Sarcoma, half reached primary completion within 72 months of starting (the median), counting those still running; a quarter within 47 and three quarters within 294. This study's planned 59 months is below that.

Counting every sponsor, half of 97 studies reached it within 66 months; a quarter within 42 and three quarters within 294.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 4, 2025
First posted
Nov 13, 2025
StartActual
Jul 1, 2025
Primary completionEst.
Jun 30, 2030
CompletionEst.
Jan 1, 2031
Last update
Nov 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
Mount Sinai Hospital, University of Toronto is now Recruiting
Nov 2, 2026
Eligibility
1 inclusion criterion edited; 1 exclusion criterion edited, 1 added
What changed in the criteria
Inclusion criteria
  • EditedHas an iPhone or Android phonesmartphone
Exclusion criteria
  • EditedDiagnosis of atypical lipomatous tumor or dermatofibrosarcoma protuberans
  • AddedDiagnosis of dermatofibrosarcoma protuberans
Nov 2, 2026
Primary outcomes
2 edited, 11 time frame changed, 5 added, 3 removed
What changed in the outcomes
  • EditedGaitWalking asymmetryTime frame: From enrolment to 1 year post-operative → From enrolment two years postoperative
  • ChangedBefore Total time activeNow Move timeTime frame: From enrolment to 1 year post-operative → From enrolment two years postoperative
  • AddedWalking SteadinessTime frame: From enrolment two years postoperative
  • AddedDouble Support TimeTime frame: From enrolment two years postoperative
  • AddedWalking SpeedTime frame: From enrolment two years postoperative
  • AddedStep LengthTime frame: From enrolment two years postoperative
  • AddedDemographic SurveyTime frame: Enrolment
  • RemovedDistinct activity periodsTime frame: From enrolment to 1 year post-operative
  • RemovedMaximal oxygen consumption (VO2 max)Time frame: From enrolment to 1 year post-operative
  • RemovedHeart rateTime frame: From enrolment to 1 year post-operative
  • Time frameStep countFrom enrolment to one year post-operative → From enrolment to two years postoperative
  • Time frameDistance travelledFrom enrolment to 1 year post-operative → From enrolment two years postoperative
  • Time frameFlights of stairs climbedFrom enrolment to 1 year post-operative → From enrolment to two years postoperative
  • Time framePROMIS Global HealthFrom enrolment to 1 year post-operative → From enrolment to two years postoperative
  • Time framePROMIS Self EfficacyFrom enrolment to 1 year post-operative → From enrolment to two years postoperative
  • Time framePROMIS Pain InterferenceFrom enrolment to 1 year post-operative → From enrolment to two years postoperative
  • Time framePROMIS Physical FunctionFrom enrolment to 1 year post-operative → From enrolment to two years postoperative
  • Time framePROMIS Upper Extremity FunctionFrom enrolment to 1 year post-operative → From enrolment to two years postoperative
  • Time frameToronto Extremity Salvage Score Lower ExtremityFrom enrolment to 1 year post-operative → From enrolment to two years postoperative
  • Time frameToronto Extremity Salvage Score Upper ExtremityFrom enrolment to 1 year post-operative → From enrolment to two years postoperative
  • Time frameHeart rate variabilityFrom enrolment to 1 year post-operative → From enrolment to two years postoperative
Nov 2, 2026
Documents
Title
Activation Sarcoma: PROMIS and Mobility Evaluation in Sarcoma Patients
Nov 2, 2026
Show all 1 update
  1. Nov 2, 2026
    Mount Sinai Hospital, University of Toronto is now Recruiting
    Eligibility 1 inclusion criterion edited; 1 exclusion criterion edited, 1 added
    What changed in the criteria
    Inclusion criteria
    • EditedHas an iPhone or Android phonesmartphone
    Exclusion criteria
    • EditedDiagnosis of atypical lipomatous tumor or dermatofibrosarcoma protuberans
    • AddedDiagnosis of dermatofibrosarcoma protuberans
    Primary outcomes 2 edited, 11 time frame changed, 5 added, 3 removed
    What changed in the outcomes
    • EditedGaitWalking asymmetryTime frame: From enrolment to 1 year post-operative → From enrolment two years postoperative
    • ChangedBefore Total time activeNow Move timeTime frame: From enrolment to 1 year post-operative → From enrolment two years postoperative
    • AddedWalking SteadinessTime frame: From enrolment two years postoperative
    • AddedDouble Support TimeTime frame: From enrolment two years postoperative
    • AddedWalking SpeedTime frame: From enrolment two years postoperative
    • AddedStep LengthTime frame: From enrolment two years postoperative
    • AddedDemographic SurveyTime frame: Enrolment
    • RemovedDistinct activity periodsTime frame: From enrolment to 1 year post-operative
    • RemovedMaximal oxygen consumption (VO2 max)Time frame: From enrolment to 1 year post-operative
    • RemovedHeart rateTime frame: From enrolment to 1 year post-operative
    • Time frameStep countFrom enrolment to one year post-operative → From enrolment to two years postoperative
    • Time frameDistance travelledFrom enrolment to 1 year post-operative → From enrolment two years postoperative
    • Time frameFlights of stairs climbedFrom enrolment to 1 year post-operative → From enrolment to two years postoperative
    • Time framePROMIS Global HealthFrom enrolment to 1 year post-operative → From enrolment to two years postoperative
    • Time framePROMIS Self EfficacyFrom enrolment to 1 year post-operative → From enrolment to two years postoperative
    • Time framePROMIS Pain InterferenceFrom enrolment to 1 year post-operative → From enrolment to two years postoperative
    • Time framePROMIS Physical FunctionFrom enrolment to 1 year post-operative → From enrolment to two years postoperative
    • Time framePROMIS Upper Extremity FunctionFrom enrolment to 1 year post-operative → From enrolment to two years postoperative
    • Time frameToronto Extremity Salvage Score Lower ExtremityFrom enrolment to 1 year post-operative → From enrolment to two years postoperative
    • Time frameToronto Extremity Salvage Score Upper ExtremityFrom enrolment to 1 year post-operative → From enrolment to two years postoperative
    • Time frameHeart rate variabilityFrom enrolment to 1 year post-operative → From enrolment to two years postoperative
    Title Activation Sarcoma: PROMIS and Mobility Evaluation in Sarcoma Patients
    + 1 other change: description

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07227961
Responsible party
Sponsor
First posted
Nov 13, 2025
Start date
Jul 1, 2025
Primary completion
Jun 30, 2030 (estimated)
Completion
Jan 1, 2031 (estimated)
Last update
Nov 2, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion